Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07248696 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is aimed to evaluate the efficacy and safety of tislelizumab combined with chemotherapy and response-adapted radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma
Trial Details
NCT Number NCT07248696
Lead Sponsor Chongqing University Cancer Hospital
Conditions
(from sponsor)		 Nasopharyngeal Cancinoma (NPC)
Related terms Nasopharyngeal Carcinoma
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov